Lantern Pharma doses first two patients in LP-284 trial

Lantern Pharma announced the dosing of the first two patients in the Phase 1 clinical trial evaluating Lantern’s investigational new drug LP-284 in patients with relapsed or refractory non-Hodgkin’s lymphoma, or NHL, including mantle cell lymphoma, or MCL, and double hit lymphoma, or DHL, and other high-grade B-cell lymphomas, or HGBL, as well as other select solid tumors and sarcomas. Recently, Lantern Pharma’s AI platform, RADR is expected to exceed 100 billion data points during 2024, and has been crucial in uncovering and accelerating indications for LP-284 as well as other drug-candidates that are in development.